| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 15.93 | 0.9% | 43.8% |
| Total Income | 15.93 | 0.9% | 43.8% |
| Expenditure | 17.51 | 0.5% | 33.6% |
| PBT | — | ||
| Net Profit | -1.75 | 17.4% | 205.4% |
| OPM | -9.95% | 1.55pp | 16.78pp |
| NPM | -11.01% | 1.72pp | 16.88pp |
| EPS | -0.05 | 0.0% | 200.0% |
Rockwell Medical Announces Q3 2025 Results: Net Sales $15.9M
04 May 2026 · 4 May, 7:25 am
Summary
Rockwell Medical announced its third quarter 2025 financial results, with net sales of $15.9 million. The company achieved profitability on an Adjusted EBITDA basis for the quarter and increased its cash position to $23.7 million. Net loss for the quarter was $1.8 million, a decrease compared to net income of $1.7 million in the same period of 2024. The company reiterates its 2025 guidance for net sales to be between $65 million and $70 million.
Key Highlights
- 1
Net sales for the third quarter 2025 were $15.9 million.
- 2
The company reiterates its 2025 guidance for net sales to be between $65 million and $70 million.
- 3
Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the third quarter 2025.
- 4
Cash position increased to $23.7 million as of September 30, 2025.
- 5
Gross margin for the third quarter 2025 was 14%, or 18% excluding restructuring costs.
- 6
Net loss for the third quarter 2025 was $1.8 million, compared to net income of $1.7 million for the same period in 2024.
- 7
Adjusted EBITDA for the third quarter 2025 was $50,000, compared to $2.8 million for the third quarter of 2024.
Management Comments
Mark Strobeck
Ph.D.
"During the third quarter, we continued to right-size our organization to enhance operational efficiency and support long-term growth, while consistently meeting customer demand," said Mark Strobeck, Ph.D., Rockwell Medical’s President and CEO. "Our proven track record of exceptional service, product quality, and manufacturing redundancy ensures uninterrupted supply of hemodialysis concentrates to dialysis providers treating patients with end-stage renal disease. Looking ahead, we are advancing targeted business development opportunities to expand our product portfolio and geographic footprint, while maintaining strict expense discipline and accelerating gross margin expansion on our path toward sustainable profitability."
Informational and educational content only. Not investment advice.